Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug

FEBS Letters

Volumn 328, Issue 3, 1993, Pages 225-229

  Rabizadeh, Ester ^a   Shaklai, Mati ^a   Nudelman, Abraham ^b   Eisenbach, Lea ^c   Rephaeli, Ada ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Butyric acid; Butyric acid prodrug; c jun; c myc; Differentiation; Proliferation

Indexed keywords

BUTYRIC ACID; PIVALOYLOXYMETHYL BUTYRIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; GENE EXPRESSION; HUMAN; LEUKEMIA CELL; ONCOGENE; ONCOGENE C MYC; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BUTYRATES; CELL DIFFERENTIATION; CELL DIVISION; COMPARATIVE STUDY; GENE EXPRESSION REGULATION; HUMAN; LEUKEMIA, PROMYELOCYTIC, ACUTE; PRODRUGS; PROTO-ONCOGENE PROTEINS C-JUN; PROTO-ONCOGENE PROTEINS C-MYC; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0027316830     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/0014-5793(93)80932-K     Document Type: Article

References (21)

1. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA.